Senseonics Holdings (SENS) earnings call transcripts

Management framed Q2 as evidence that in-house commercialization is improving growth and margins while expanding access and advancing its product pipeline.

Management framed Q1 as early proof that direct commercial control can improve growth and margins while funding a longer-term product pipeline.

Management framed 2025 as a commercial and financial transformation, with 2026 growth depending on direct selling, patient renewals, pump integration, and Europe.

Management framed Q3 as evidence that Eversense 365 demand is accelerating, while emphasizing that commercial control and margin gains depend on a complex transition from Ascensia.